Acne Vulgaris Clinical Trial
Official title:
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne Vulgaris
This study will compare two different acne treatments for the treatment of acne. Half of the participants will receive two marketed acne products (cleanser and leave-on topical treatment), while the other half of the participants will receive a marketed cleanser and a light-therapy device.
Acne is a common chronic skin disease involving blockage and/or inflammation of the hair
follicles and their accompanying sebaceous gland.
Benzoyl peroxide (BPO) is one of the most effective and well-studied over-the-counter (OTC)
acne therapies, is generally regarded as safe and effective and is considered as a first-line
treatment for acne. Topical BPO monotherapy products for at-home acne treatment have been
available for OTC use for more than 30 years and studies have indicated that a low dose of
BPO may be an effective approach for treating acne using an OTC product when applied
consistently to larger areas of the face due primarily to its effects against acne-causing
bacteria.
BPO has anti-inflammatory and keratolytic properties, but is thought to act primarily to
control P. acnes by releasing reactive oxygen species that are toxic to the bacteria. The
most common side effect of topical BPO treatment is skin irritation, which can include
erythema, burning, and peeling.
As an alternative to topical OTC standard of care therapies, research has also shown the
benefits of red and blue light therapy in the treatment of mild to moderate acne, with red
and blue light shown to target the acne-causing bacteria and have an effect on inflammation
reduction.
Light-based therapies have been successfully used to treat dermatological conditions since
the early 1900's, with various parts of the electromagnetic spectrum (i.e. UV, visible,
near-Infrared, etc.) demonstrating different benefits. Light-emitting diodes (LEDs) offer
delivery of light to the skin in a gentler manner as compared to light delivered by lasers
primarily due to the lower energy output. It has been reported that LEDs do not deliver
enough power to damage tissues and do not have the same risk of accidental eye damage that
lasers do. Visible-LED light therapy has been deemed a non-significant risk by the Food and
Drug Administration and has been approved for use in humans.
This study will look to compare the acne clearing efficacy and tolerance of two different
acne treatments: a currently marketed 2.5% BPO full-face topical OTC treatment, and an
Investigational red and blue light acne light therapy mask, to determine if the acne
resolution efficacy of the Investigational mask is as effective as a current OTC standard of
care for at-home treatment of mild to moderate acne.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |